Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2014

01-05-2014 | Review

Development of anticancer drugs based on the hallmarks of tumor cells

Authors: Natalia Bailón-Moscoso, Juan Carlos Romero-Benavides, Patricia Ostrosky-Wegman

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

Cancer remains a public health problem with a high unmet medical demand. However, in recent decades, the knowledge of several functional molecular and biological traits that distinguish tumor cells from normal cells, known as the hallmarks of cancer as described by Hannahan and Weinberg, has led to new and modern therapeutic approaches against this disease. Most cancer drugs are deliberately developed for specific molecular targets that involve these hallmarks. In this review, we address the currently available cancer drugs and development of new drugs from the perspective of their interaction with these hallmarks as well as the pathways and mechanisms involved.
Literature
1.
Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006;2:689–700.PubMedCrossRef
2.
3.
4.
5.
J.A. Engelman. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Cancer. 9 (2009).
6.
Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal. 2009;2:ra2.PubMedPubMedCentralCrossRef
7.
Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7:1851–63.PubMedCrossRef
8.
Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012;319:1–7.PubMedCrossRef
9.
S. Pyndiah, S. Tanida, K.M. Ahmed, E.K. Cassimere, C. Choe, D. Sakamuro. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci. Signal. 4 (2011) ra19.
10.
Larsson L-G, Henriksson MA. The yin and yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res. 2010;316:1429–37.PubMedCrossRef
11.
Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett. 2003;197:125–30.PubMedCrossRef
12.
Lee MO, Han SY, Jiang S, Park JH, Kim SJ. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem Pharmacol. 2000;59:485–96.PubMedCrossRef
13.
Sarkar SA, Sharma RP. Expression of c-Myc and other apoptosis-related genes in Swiss Webster mouse fetuses after maternal exposure to all trans-retinoic acid. Reprod Toxicol. 2002;16:245–52.PubMedCrossRef
14.
15.
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17.PubMedPubMedCentralCrossRef
16.
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524–8.PubMedPubMedCentralCrossRef
17.
18.
Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36:131–49.PubMedCrossRef
19.
Malumbres M, Barbacid M. Cell cycle. CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.PubMedCrossRef
20.
Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2:910–7.PubMedCrossRef
21.
Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547–66.PubMedCrossRef
22.
Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 2005;5:366–73.PubMedCrossRef
23.
Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jones JA, et al. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia. 2012;26:1442–4.PubMedPubMedCentralCrossRef
24.
Cirillo D, Pentimalli F, Giordano A. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors. Curr Med Chem. 2011;18:2854–66.PubMedCrossRef
25.
Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3–11.PubMedCrossRef
26.
27.
28.
Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876–85.PubMedCrossRef
29.
Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis. 2001;6:191–7.PubMedCrossRef
30.
31.
Ghobrial I, Witzig T, Adjei A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178–94.PubMedCrossRef
32.
van Geelen CM, Pennarun B, Le PT, de Vries EG, de Jong S. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer. 2011;11:39.PubMedPubMedCentralCrossRef
33.
34.
Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer. 2009;9:724–37.PubMedCrossRef
35.
Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006;13:921–6.PubMedCrossRef
36.
Lu P, Yang X, Huang Y, Lu Z, Miao Z, Liang Q, et al. Antitumor activity of a combination of rAd2p53 adenoviral gene therapy and radiotherapy in esophageal carcinoma. Cell Biochem Biophys. 2011;59:147–52.PubMedCrossRef
37.
Partridge M, Costea DE, Huang X. The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg. 2007;36:1123–38.PubMedCrossRef
38.
Tovar C, Rosinski J, Filipovic Z. From the cover: small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Med Sci. 2006;103:188–1893.
39.
Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005;12 Suppl 1:942–61.PubMedCrossRef
40.
Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408–18.PubMedCrossRef
41.
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–8.PubMedCrossRef
42.
Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8:121–32.PubMedCrossRef
43.
Reed JC. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 2006;13:1378–86.PubMedCrossRef
44.
Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989–1000.PubMedCrossRef
45.
Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 2007;13:7254–63.PubMedCrossRef
46.
M.H. Kang, C.P. Reynolds. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy targeting mitochondrial apoptotic pathways. Clin. Cancer Res. (2009) 1126–1132.
47.
Hann CL, Daniel VC. E. a Sugar, I. Dobromilskaya, S.C. Murphy, L. Cope, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68:2321–8.PubMedPubMedCentralCrossRef
48.
Kabore AF, Johnston JB, Gibson SB. Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr Cancer Drug Targets. 2004;4:147–63.PubMedCrossRef
49.
D’Amelio M, Tino E, Cecconi F. The apoptosome: emerging insights and new potential targets for drug design. Pharm Res. 2008;25:740–51.PubMedCrossRef
50.
Yang J-Y, Michod D, Walicki J, Widmann C. Surviving the kiss of death. Biochem Pharmacol. 2004;68:1027–31.PubMedCrossRef
51.
Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61–70.PubMedCrossRef
52.
Ryan BM, O’Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35:553–62.PubMedCrossRef
53.
Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14:120–8.PubMedCrossRef
54.
55.
R. Arora, M. Shuda, A. Guastafierro, H. Feng, T. Toptan, Y. Tolstov, et al. Survivin is a therapeutic target in Merkel cell carcinoma. Sci. Transl. Med. 4 (2012) 133ra56.
56.
57.
K.-D. Yu, Z.-M. Shao. The two faces of autophagy and the pathological underestimation of DCIS. Nat. Rev. Cancer. 11 (2011) 618; author reply 618.
58.
Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R, et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 2009;16:87–93.PubMedCrossRef
59.
60.
Kubisch J, Türei D, Földvári-Nagy L. Z. a Dunai, L. Zsákai, M. Varga, et al. Complex regulation of autophagy in cancer—integrated approaches to discover the networks that hold a double-edged sword. Semin Cancer Biol. 2013;23:252–61.PubMedCrossRef
61.
62.
Bodnar AG, Ouellette M, Frolkis M, Holt S, Chiu C, Morin G, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349–52.PubMedCrossRef
63.
Guittat L, Alberti P, Gomez D, De Cian A, Pennarun G, Lemarteleur T, et al. Targeting human telomerase for cancer therapeutics. Cytotechnology. 2004;45:75–90.PubMedPubMedCentralCrossRef
64.
65.
Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology. 2005;42:1127–36.PubMedCrossRef
66.
Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat. 2006;96:73–81.PubMedCrossRef
67.
68.
69.
Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2012;5:444–56.
70.
Herbert BS. Disruption of telomere homeostasis as a new cancer treatment strategy. Memo - Mag. Eur Med Oncol. 2009;2:21–4.
71.
72.
Kim M-Y, Vankayalapati H, Shin-ya K, Wierzba K, Hurley LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J Am Chem Soc. 2002;124:2098–9.PubMedCrossRef
73.
Burger AM, Dai F, Schultes CM, Reszka AP, Moore MJ. J. a Double, et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005;65:1489–96.PubMedCrossRef
74.
Leonetti C, Scarsella M, Riggio G, Rizzo A, Salvati E, D’Incalci M, et al. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin Cancer Res. 2008;14:7284–91.PubMedCrossRef
75.
Chen Y, Qu K, Zhao C, Wu L, Ren J, Wang J, et al. Insights into the biomedical effects of carboxylated single-wall carbon nanotubes on telomerase and telomeres. Nat Commun. 2012;3:1074.PubMedCrossRef
76.
Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–84.PubMedCrossRef
77.
Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003;3:55–63.PubMedCrossRef
78.
Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst. 2005;97:632–42.PubMedCrossRef
79.
80.
El Touny L, Banerjee P. Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem Biophys Res Commun. 2007;361:169–75.PubMedPubMedCentralCrossRef
81.
Xu J-H, Guo X-Z, Ren L-N, Shao L-C, Liu M-P. KAI1 is a potential target for anti-metastasis in pancreatic cancer cells. World J Gastroenterol. 2008;14:1126–32.PubMedPubMedCentralCrossRef
82.
Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007;257:16–35.PubMedCrossRef
83.
84.
Wu L, Zhu L, Shi W-H, Zhang J, Ma D, Yu B. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol. 2009;602:124–31.PubMedCrossRef
85.
Hynes NE. H. a Lane. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.PubMedCrossRef
86.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550–65.PubMedCrossRef
87.
Weigelt B, Peterse JL. L.J. van ’t Veer. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602.PubMedCrossRef
88.
Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–75.PubMedCrossRef
89.
Weinberg RA. Perspectives in cancer research oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 1989;49:3713–21.PubMed
90.
91.
Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727–39.PubMedCrossRef
92.
93.
Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009;6:507–18.PubMedCrossRef
94.
Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J. R. a Smith, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835–44.PubMedCrossRef
95.
Ronca R, Sozzani S, Presta M, Alessi P. Delivering cytokines at tumor site: the immunocytokine-conjugated anti-EDB-fibronectin antibody case. Immunobiology. 2009;214:800–10.PubMedCrossRef
96.
97.
Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 2009;6:395–404.PubMedCrossRef
98.
Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol. 2008;5:250–67.PubMedCrossRef
99.
Cragg GM, Newman DJ. Nature: a vital source of leads for anticancer drug development. Phytochem Rev. 2009;8:313–31.CrossRef
100.
101.
Legg JA, Herbert JMJ, Clissold P, Bicknell R. Slits and roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008;11:13–21.PubMedCrossRef
102.
Koch AW, Mathivet T, Larrivée B, Tong RK, Kowalski J, Pibouin-Fragner L, et al. Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell. 2011;20:33–46.PubMedCrossRef
103.
Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220–8.PubMedCrossRef
104.
105.
Guaman-Ortiz LM, Giansanti V, Dona F, Scovassi I. Pharmacological effects of PARP inhibitors on cancer and other diseases. Curr Enzym Inhib. 2011;7:244–58.CrossRef
106.
107.
Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat. 2009;12:153–6.PubMedCrossRef
108.
Jagtap P, Szabó C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4:421–40.PubMedCrossRef
109.
Annunziata C, O’Shaughnessy J. PARP as a novel therapeutic target in cancer. Clin Cancer Res. 2011;16:4517–26.CrossRef
110.
Begg AC. F. a Stewart, C. Vens. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239–53.PubMedCrossRef
111.
D. Davidson, Y. Wang, R. Aloyz, L. Panasci. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Invest. New Drugs. (2013) 1–8.
112.
113.
Ekblad T, Camaioni E, Schüler H, Macchiarulo A. PARP inhibitors: polypharmacology versus selective inhibition. FEBS J. 2013;280:3563–75.PubMedCrossRef
114.
Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in cancer. Front Oncol. 2013;3:1–11.CrossRef
115.
Do K, Chen A. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res. 2013;19:977–84.PubMedCrossRef
116.
117.
De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol. 2013;3:228.PubMedPubMedCentralCrossRef
118.
Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol. 2010;7:508–19.PubMedCrossRef
119.
120.
121.
Matsuoka S. B. a Ballif, A. Smogorzewska, E.R. McDonald, K.E. Hurov, J. Luo, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–6.PubMedCrossRef
122.
Helleday T, Petermann E, Lundin C, Hodgson B. R. a Sharma. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.PubMedCrossRef
123.
Yang D, Halaby M, Li Y, Hibma JC, Burn P. Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discov Today. 2011;16:332–8.PubMedCrossRef
124.
A. Nadkarni, M. Shrivastav, A.C. Mladek, P.M. Schwingler, P.T. Grogan, J. Chen, et al. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J. Neurooncol. (2012).
125.
Rainey M, Charlton M, Stanton R, Kastan M. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008;68:7466–74.PubMedPubMedCentralCrossRef
126.
127.
Kops GJPL. B. a a Weaver, D.W. Cleveland. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5:773–85.PubMedCrossRef
128.
Zhivotovsky B, Kroemer G. Apoptosis and genomic instability. Nat Rev Mol Cell Biol. 2004;5:752–62.PubMedCrossRef
129.
Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14:1639–48.PubMedCrossRef
130.
Kitzen JJEM. M.J. a de Jonge, J. Verweij. Aurora kinase inhibitors. Crit Rev Oncol Hematol. 2010;73:99–110.PubMedCrossRef
131.
Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10:262–7.PubMedCrossRef
132.
Keen N, Taylor S. Mitotic drivers—inhibitors of the Aurora B kinase. Cancer Metastasis Rev. 2009;28:185–95.PubMedCrossRef
133.
134.
135.
136.
Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9:447–64.PubMedCrossRef
137.
Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer’s stygian link to the “Warburg effect” and a pivotal target for effective therapy. Semin Cancer Biol. 2009;19:17–24.PubMedCrossRef
138.
Cohen S, Flescher E. Methyl jasmonate: A plant stress hormone as an anti-cancer drug. Phytochemistry. 2009;70:1600–9.PubMedCrossRef
139.
Raviv Z, Cohen S, Reischer-Pelech D. The anti-cancer activities of jasmonates. Cancer Chemother Pharmacol. 2013;71:275–85.PubMedCrossRef
140.
Vander Heiden M, Christofk H, Schuma E, Subtelny AO, Sharfi H, Harlow E, et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol. 2010;79:1118–24.PubMedCrossRef
141.
142.
143.
Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 2011;30:4297–306.PubMedCrossRef
144.
Iqbal MA, Bamezai RNK. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One. 2012;7:e36764.PubMedPubMedCentralCrossRef
145.
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.PubMedCrossRef
146.
Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010;107:2037–42.PubMedPubMedCentralCrossRef
147.
Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004;305:200–5.PubMedCrossRef
148.
Sharma SV, Settleman J. Exploiting the balance between life and death: targeted cancer therapy and “oncogenic shock”. Biochem Pharmacol. 2010;80:666–73.PubMedCrossRef
149.
150.
Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 2006;6:613–25.PubMedCrossRef
151.
Katz JB, Muller AJ, Prendergast GC. T-cell tolerance and tumoral immune escape. Immunol Rev. 2008;2008(222):206–21.CrossRef
152.
Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008;27:3889–900.PubMedCrossRef
153.
154.
Yared J, Kimball A, Baer MR, Bahrain H, Auerbach M. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13:253–7.PubMedCrossRef
155.
156.
A.E. Moran, M. Kovacsovics-Bankowski, A.D. Weinberg. The TNFRs OX40, 4–1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. (2013) 1–8.
157.
Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4371–7.PubMedCrossRef
158.
Houot R, Kohrt H, Goldstein MJ, Levy R. Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev. 2011;30:97–109.PubMedCrossRef
159.
Peggs KS. S. a Quezada, C. a Chambers, A.J. Korman, J.P. Allison. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717–25.PubMedPubMedCentralCrossRef
160.
161.
162.
Aggarwal BB. R. V Vijayalekshmi, B. Sung. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15:425–30.PubMedCrossRef
163.
Kundu J, Surh Y. Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals. Mutat Res. 2005;591:123–46.PubMedCrossRef
164.
165.
166.
167.
Cuzick J, Otto F. J. a Baron, P.H. Brown, J. Burn, P. Greenwald, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501–7.PubMedCrossRef
168.
Ben-Baruh A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52.CrossRef
169.
Galzi J-L, Hachet-Haas M, Bonnet D, Daubeuf F, Lecat S, Hibert M, et al. Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications. Pharmacol Ther. 2010;126:39–55.PubMedCrossRef
170.
Trotta T, Costantini S, Colonna G. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design. Mol Immunol. 2009;47:332–9.PubMedCrossRef
171.
172.
Lin Y, Bai L, Chen W, Xu S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010;14:45–55.PubMedPubMedCentralCrossRef
173.
Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70:i104–8.PubMedCrossRef
174.
Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904–10.PubMedCrossRef
175.
Shen H-M, Tergaonkar V. NFjB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis. 2009;14:348–63.PubMedCrossRef
176.
Brown ER. K. a Charles, S. a Hoare, R.L. Rye, D.I. Jodrell, R.E. Aird, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol. 2008;19:1340–6.PubMedCrossRef
177.
Zidi I, Mestiri S, Bartegi A, Ben Amor N. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27:185–98.PubMedCrossRef
178.
Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87:401–6.PubMedCrossRef
179.
Olivier S, Robe P, Bours V. Can NF-kB be a target for novel and efficient anti-cancer agents ? Biochem Pharmacol. 2006;72:1054–68.PubMedCrossRef
180.
Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297–309.PubMedCrossRef
181.
182.
183.
Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs. 2009;20:880–92.PubMedCrossRef
184.
Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: natural inhibitors of NF-kappaB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci. 2008;65:2979–99.PubMedCrossRef
185.
J. Shortt, a K. Hsu, R.W. Johnstone. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. (2013) 1–12.
Metadata
Title
Development of anticancer drugs based on the hallmarks of tumor cells
Authors
Natalia Bailón-Moscoso
Juan Carlos Romero-Benavides
Patricia Ostrosky-Wegman
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1649-y

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue

Research Article

Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation

Review

Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis

Research Article

Circulatory miR-628-5p is downregulated in prostate cancer patients

Research Article

Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma

Research Article

Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue

Research Article

Survivin mRNA-circulating tumor cells predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits